Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Starpharma Holdings Ltd. (SPHRY : OTC)

• Company Description    Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia. Number of Employees: 40

• Price / Volume Information    Yesterday's Closing Price: $0.67 Daily Weekly Monthly 20 Day Moving Average: 169 shares Shares Outstanding: 41.82 (millions) Market Capitalization: $28.10 (millions) Beta: 0.76 52 Week High: $0.80 52 Week Low: $0.47 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.36% 4.82% 12 Week 8.39% -5.60% Year To Date 4.46% -2.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4-6 Southampton Crescent - Abbotsford,C3 3067 AUS ph: 61-3-8532-2700 fax: 61-3-9510-5955 investor.relations@starpharma.com http://www.starpharma.com

• General Corporate Information    Officers Cheryl Maley - Chief Executive Officer Robert B Thomas - Chairman David McIntyre - Director Lynda Cheng - Director Jeff R Davies - Director Peer Information Starpharma Holdings Ltd. (CORR.) Starpharma Holdings Ltd. (RSPI) Starpharma Holdings Ltd. (CGXP) Starpharma Holdings Ltd. (BGEN) Starpharma Holdings Ltd. (GTBP) Starpharma Holdings Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 855563102 SIC: 8731 Fiscal Year Fiscal Year End: June Last Reported Quarter: - Next Expected EPS Date: 08/28/25 Share - Related Items Shares Outstanding: 41.82 Most Recent Split Date: (:1) Beta: 0.76 Market Capitalization: $28.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/28/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.86 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 5.41 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 4.93 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 0.36 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.07 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 6.25

Powered by Zacks Investment Research ©